The process boosts glucose-dependent insulin production while reducing glucagon release from the pancreatic α-cells, resulting in decreased blood sugar levels and a minimized risk of hypoglycemia because of increased insulin and decreased glucagon secretion [13]. The gene discussed is INS; the disease is Hypoglycemia.